Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

FDA Approves Extended-Release Amantadine (GOCOVRI™) for Treatment of Dyskinesia

Statement from the Parkinson's Foundation Medical Director, Michael Okun, MD

"Today, Adamas announces FDA approval of an extended release amantadine capsule called GOCOVRI. This drug will provide a practical once a day solution for dyskinesia management and reducing "off" time. Patients who are currently well managed using multiple doses per day of generic amantadine for dyskinesia will not likely derive additional symptomatic benefits from switching to once a day dosing; however, patients experiencing side effects from amantadine may wish to discuss options with their neurologist.

Both GOCOVRI and generic amantadine use is linked to a risk of side effects such as dizziness, hallucinations or blotching on the skin of the legs.  If you are considering starting this medicine or switching to this medicine we recommend consulting with your doctor.

In an independent Parkinson's Foundation study prior to this approval, we found that generic amantadine use improved dyskinesia in patients.  However, amantadine use does have a risk of side effects including insomnia and hallucinations. GOCORVI has been designed to limit the risk of these complications and it will not carry generic amantadine's warning for insomnia."

Call our Helpline, 1-800-4PD-INFO, or visit www.GOCOVRI.com for more information.

About the Parkinson's Foundation

The Parkinson's Foundation is working toward a world without Parkinson's disease. Formed by the merger of National Parkinson Foundation (NPF) and the Parkinson's Disease Foundation (PDF), the mission of the Parkinson's Foundation is to invest in promising scientific research that will end Parkinson's disease and improve the lives of people with Parkinson's, and their families, through improved treatments, support and the best care. For more information, visit www.parkinson.org, or call (800) 4PD-INFO (473-4636).

About Parkinson's Disease (PD)

Affecting an estimated one million Americans and 10 million worldwide, PD is the second-most common neurodegenerative disease after Alzheimer's and is the 14th-leading cause of death in the United States. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression) as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for PD and 60,000 new cases are diagnosed each year in the United States alone.

# # #

Friday, August 25, 2017
The National Parkinson Foundation Awards Four Innovative Research Grants
Wednesday, November 4, 2015

One Million Dollar Investment in Clinical Research in Parkinson’s Disease

MIAMI — The National Parkinson Foundation (NPF) announced today that it has funded four new grants in Parkinson’s disease (PD) research. The four grants target key scientific questions about gender differences in Parkinson’s, cognition and inflammation.

Should Patients and Families Be Considering Tasigna (Nilotinib) Therapy for Parkinson’s Disease? The NPF Recommends Further Study but Not Clinical Use of this Investigational Drug
Wednesday, October 21, 2015

Tasigna (Nilotinib) is a leukemia drug that has recently been tested for safety in a small, phase I clinical trial on about a dozen Parkinson’s disease patients. The study had positive results that certainly warrant the continuation to a phase II trial, however it is too early for patients to seek treatment outside the setting of a clinical trial. The study was very small, and it was not placebo controlled.

NatGeo to Air Live Parkinson's DBS Surgery: What Should You Know?
Tuesday, October 20, 2015

The Parkinson’s Disease Foundation (PDF) has learned that later this week, the National Geographic Channel will air a live television broadcast of deep brain stimulation surgery for Parkinson’s disease (PD).

Parkinson's Disease Foundation and American Parkinson Disease Association Collaborate to Cultivate Future Parkinson's Scientific Leaders
Thursday, October 15, 2015

The Parkinson's Disease Foundation® (PDF®) and the American Parkinson Disease Association (APDA) are pleased to announce their collaboration on Summer Student Fellowships to support research that will help solve, treat and end Parkinson's disease.

PDF Research Advocates Highlight Unmet Needs in Parkinson’s at FDA Meeting
Tuesday, September 29, 2015

The Parkinson’s Disease Foundation (PDF) is pleased to report that five of its Research Advocates represented the community at last week’s Food and Drug Administration’s (FDA) Patient-Focused Drug Development meeting on Parkinson’s Disease in Silver Spring, MD.

National Parkinson Foundation Ohio Chapter Now Serves Entire State
Monday, September 21, 2015

Moving Day® Cleveland, A Walk for Parkinson’s, Slated for June 2016

Columbus — The National Parkinson Foundation (NPF) Central & Southeast Ohio Chapter has officially changed its name to National Parkinson Foundation Ohio. The name change signifies the expansion of service statewide to the approximately 30-50,000 Ohioans with Parkinson’s disease (PD). 

Parkinson's Disease Foundation Mobilizes Community to Address Unmet Needs of Women Living with Parkinson’s
Wednesday, September 16, 2015

The Parkinson's Disease Foundation® (PDF®) is pleased to launch its Women and PD Initiative, the first national coordinated effort dedicated to improving the health and well-being of women living with Parkinson’s disease. The initiative launches this week with a three-day conference in Florham Park, NJ.

Parkinson's Disease Foundation Highlights Under-recognized Aspects of Disease with New Online Educational Series
Tuesday, September 15, 2015

The Parkinson's Disease Foundation® (PDF®) is pleased to announce the launch of its latest series of PD ExpertBriefings — six free online seminars designed to shed light on under-recognized aspects of Parkinson's disease. The series, presented by leaders in Parkinson's research and care, begins today, Tuesday, September 15 at 1:00 PM ET.

PDF-Funded Research Paves the Way to Phase III Drug Trial
Wednesday, September 2, 2015

The Parkinson’s Disease Foundation (PDF) is pleased to announce that research initially launched with PDF funding will be tested in a phase III clinical trial opening in 2016. The study, which two of PDF’s volunteer Research Advocates are helping to oversee, is assessing the potential of the nutritional supplement inosine for the treatment of Parkinson’s disease.

The National Parkinson Foundation’s Medical Director Publishes New Book on Breakthrough Therapies for Parkinson’s Disease
Monday, August 31, 2015

Sequel to 2013 Bestseller, “Parkinson’s Treatment: 10 Secrets to a Happier Life”

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.